What is the approach to sequencing therapy for moderate-to-severe AD, what are the risks for established agents, and how have type 2 cytokine-signaling inhibitors such as dupilumab changed our approach to sequencing in the younger population?

What is the approach to sequencing therapy for moderate-to-severe AD, what are the risks for established agents, and how have type 2 cytokine-signaling inhibitors such as dupilumab changed our approach to sequencing in the younger population?

CLICK HERE FOR CME CREDIT Back to Symposium

What is the approach to sequencing therapy for moderate-to-severe AD, what are the risks for established agents, and how have type 2 cytokine-signaling inhibitors such as dupilumab changed our approach to sequencing in the younger population? 

Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Mark Lebwohl, MD

Mark Lebwohl, MD

Professor and Chairman, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York USA